Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer

Date

21 Oct 2023

Session

Poster session 20

Topics

Cancer Biology;  Tumour Immunology;  Pathology/Molecular Biology;  Translational Research;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Laura Masfarre Pinto

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

L. Masfarre Pinto1, A.S.D.F.M. Parreira2, N. Castro Unanua3, P. Rocha4, I. Morilla Ruiz5, L. Teijeira Sanchez5, S. Clavé6, N. Navarro Gorro7, R. Bach Mora8, I. Sánchez6, M.A. GALINDO CAMPOS9, A. Taus Garcia10, A. Azkárate Martínez11, R. Marse Fabregat12, B. Bellosillo Paricio13, H. Arasanz14, M. Martínez Aguillo5, E. Arriola15

Author affiliations

  • 1 Oncology Department, Hospital del Mar - Parc de Salut Mar, 08003 - Barcelona/ES
  • 2 Medical Oncology, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 3 Oncobiona/medical Oncology Dept, Hospital Universitario de Navarra, 31008 - Pamplona/ES
  • 4 Cancer Research Program, IMIM - Institut Hospital del Mar d'Investigacions Mediques, 08003 - Barcelona/ES
  • 5 Oncology Department, Complejo Hospitalario de Navarra - Royal Navarre Hospital, 31008 - Pamplona/ES
  • 6 Pathology Department, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES
  • 7 Medical Oncology Department, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES
  • 8 Oncology Department, Parc de Salut Mar, 08003 - Barcelona/ES
  • 9 Doctor Aiguader 88, IMIM - Institut Hospital del Mar d'Investigacions Mediques, 08003 - Barcelona/ES
  • 10 Medical Oncology, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES
  • 11 Medical Oncology Department, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 12 Oncology Department, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 13 Molecular Biology Department, Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES
  • 14 Dept. Medical Oncology, Complejo Hospitalario de Navarra - Royal Navarre Hospital, 31008 - Pamplona/ES
  • 15 Medical Oncology Dept., Hospital del Mar - Parc de Salut Mar, 8003 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1408P

Background

Non-small cell lung cancer (NSCLC) can harbor different KRAS mutations. Although targeted therapy is available for KRAS G12C-mutant NSCLC, immune checkpoint inhibitors (ICIs) are still the first line treatment (tx) for these patients (pts). Here we aimed to assess the outcomes on ICIs for KRAS G12C compared to KRAS non-G12C-mutant pts.

Methods

This is an observational, retrospective, multicenter study in pts with KRAS-mutant NSCLC treated with ICIs (monotherapy or combination) between January 2017 and January 2023. Targeted sequencing was performed in most cases. Clinicopathological and molecular data were collected. We evaluated pts characteristics, tx response and survival outcomes from the beginning of ICIs in KRAS G12C vs non-G12C tumors.

Results

A total of 169 pts were included. NGS was performed in 105 pts, STK11 and TP53 were the most frequent co-mutated genes present in 4.4%/15% G12C/non-G12C (p=0.110) and 20%/35% G12C/non-G12C (p=0.143), respectively. There were no differences in median progression free survival (PFS) between G12C/non-G12C (8.8 vs 7.1 months(m) respectively p=0.727). In the multivariate analysis, PD-L1 negative tumors and ECOG ≥1 remained independently associated with worse PFS (p=0.010 and p= 0.002 respectively). Regarding overall survival (OS), harboring a G12C mutation was associated with a better OS compared with non-G12C tumors (mOS 16.2m vs 10.4m p=0.033), conversely PD-L1 negative tumors and basal ECOG of ≥1 was associated with worse OS (p= 0.002 and p<0.001 respectively).

Table: 1408P

Patient’s characteristics

N (%) G12C (n=75) Non-G12c (n=94) p-value
Median age 62.9 63.8 0.471
Sex 0.220
Male 45 (60) 66 (70.2)
Female 30 (40) 28 (29.7)
Tobacco 0.203
Former 34 (45.4) 53 (56,4)
Current 41 (54.6) 41 (43.6)
Stage 0.630
I-III 17 (21.7) 22 (23,4)
IV 58 (78.3) 72 (76.6)
M1 CNS 14 (18.6) 24 (25.5) 0.381
M1 liver 14 (18.6) 20 (21.3) 0.820
ICIs treatment line 0.604
1 57 (76) 75 (80)
≥2 18 (24) 19 (20)
PD-L1 0.397
Negative (0%) 17 (22.7) 30 (32)
Positive (≥0%) 58 (77.3) 64 (68)
ECOG 0.887
0 31 (41.4) 41 (43.6)
≥1 44 (58.6) 53 (56.4)
.

Conclusions

Our work shows that patients with KRAS non-G12C tumors are more frequently PD-L1 negative and harbor a higher proportion of STK11 co-mutations conditioning a worse OS on immunotherapy treatment. Innovative therapeutic strategies need to be investigated for these patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

L. Masfarre Pinto: Other, Personal, Other, Travel Support: Kyowa Kirin. N. Castro Unanua: Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Ownership Interest, Travel, congress registration: Merck, Roche; Financial Interests, Personal, Ownership Interest, Grant support: Expert Degree in Immuno-Oncology: Bristol Myers Squibb; Financial Interests, Personal, Ownership Interest, Travel: Pfizer. P. Rocha: Non-Financial Interests, Personal, Other, Travel Support: AstraZeneca. B. Bellosillo Paricio: Other, Personal, Other, Grant: Thermo Fisher, Roche Diagnostics, Roche Farma, AstraZeneca; Other, Personal, Other, Consultant: Amgen, AstraZeneca, Janssen, Novartis; Other, Personal, Speaker’s Bureau: Janssen, Merck-Serono, Novartis, Qiagen, Thermo Fisher, Pfizer, Bristol Myers Squibb. H. Arasanz: Other, Personal, Advisory Board: AstraZeneca; Other, Personal and Institutional, Other, Clinical Trial Coordination: Ferrer Farma; Other, Personal, Other, accommodation/travel expenses: Takeda, MSD, Angelini Farma. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.